DC
SEEL

Davenport & Co’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Davenport & Co’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38
Closed -$26.8K – 1122
2023
Q3 		$26.8K Buy
38
+3
+9% +$12.9K ﹤0.01% 1043
2023
Q2 		$162K Hold
35
– – ﹤0.01% 1014
2023
Q1 		$93.7K Hold
35
– – ﹤0.01% 1022
2022
Q4 		$92K Hold
35
– – ﹤0.01% 981
2022
Q3 		$140K Hold
35
– – ﹤0.01% 945
2022
Q2 		$92K Hold
35
– – ﹤0.01% 968
2022
Q1 		$114K Sell
35
-20
-36% -$86K ﹤0.01% 1032
2021
Q4 		$343K Sell
55
-12
-18% -$92.1K ﹤0.01% 866
2021
Q3 		$623K Sell
67
-4
-6% -$34.4K ﹤0.01% 668
2021
Q2 		$722K Buy
71
+8
+13% +$131K 0.01% 550
2021
Q1 		$1.21M Buy
63
+27
+75% +$315K 0.01% 353
2020
Q4 		$216K Buy
+36
New +$141K ﹤0.01% 729
2020
Q3 		– Sell
-5
Closed -$20K – 759
2020
Q2 		$20K Hold
5
– – ﹤0.01% 702
2020
Q1 		$10K Buy
+5
New +$18.6K ﹤0.01% 662

Other funds holding SEEL

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Davenport & Co's SEEL Position: Q4 2023 in Review

Davenport & Co sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 38 shares — an estimated $26.8K sold.

Davenport & Co first reported a position in SEEL in Q1 2020 and held it in 14 quarters. The position peaked at $1.21M in Q1 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

  • Davenport & Co reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Davenport & Co sold 38 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $26.8K.
  • Davenport & Co first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
  • Davenport & Co's Seelos Therapeutics, Inc. Common Stock position peaked at $1.21M in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Davenport & Co's 13F filing for Q4 2023, filed 23 Jan 2024.